Sweden · Delayed Price · Currency is SEK Boule Diagnostics AB Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw a return to organic growth and strong operating cash flow, despite a 10% sales decline due to currency headwinds and one-off costs from site consolidation. Margin pressures are seen as temporary, with strategic initiatives underway to drive future profitability.
Fiscal Year 2025
-
Q4 saw sales decline due to currency headwinds and the India transition, but gross margin and cash flow improved. Structural cost reductions and operational efficiencies were achieved, with new product launches and OEM growth expected in coming years.
-
Organic growth returned in Q3 with strong instrument sales and improved margins, despite currency headwinds and lower gross profit. Strategic cost reductions and new product agreements support a positive outlook, with continued focus on margin expansion and cash flow.
-
Q2 saw a 3.3% organic sales decline, but instrument unit sales rose 17% year-over-year, with 5-Part instrument sales more than doubling at lower prices. Operating expenses dropped 47%, and positive operating cash flow was achieved, despite margin pressures from currency and costs.
-
Q1 2025 saw a 25% organic sales decline due to delayed shipments and tough prior-year comparisons, but gross margin and operating margin improved thanks to restructuring and a favorable sales mix. OEM business grew 7%, and a higher order backlog is expected to benefit Q2.
Fiscal Year 2024
-
Q4 saw stable performance with improved margins and significant cost savings from restructuring, despite a slight sales decline due to pricing and the India license model. OEM growth was strong, and a new U.S. distribution deal is set to boost future revenue.
-
Q3 saw a 6.6% sales decline, but gross margin and EBIT improved due to cost savings and a favorable mix. Major one-time costs included a SEK 265 million impairment and SEK 27 million write-down, while OEM growth and restructuring initiatives support a positive outlook for 2025.
-
Q2 saw stable performance with net sales down 2.5% year-over-year, but profitability improved due to cost reductions and efficiency gains. OEM sales and cash flow were strong, while investments in new products and veterinary expansion continue.